Raloxifene prevents the growth of uterine leiomyomas in premenopausal women

Fertility and Sterility

Volumn 81, Issue 1, 2004, Pages 132-136

  Jirecek, Stefan ^a   Lee, Andreas ^a   Pavo, Imre ^b   Crans, Gerald ^b   Eppel, Wolfgang ^a   Wenzl, Rene ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Leiomyoma; Premenopausal; Raloxifene; Sex hormone; Transvaginal ultrasound

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; FOLLITROPIN; PROLACTIN; RALOXIFENE; SEX HORMONE; TESTOSTERONE; THYROTROPIN;

ADULT; ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; ARTICLE; AUSTRIA; CANCER INHIBITION; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; DYSMENORRHEA; FEMALE; HOT FLUSH; HUMAN; LEG CRAMP; MENSTRUATION DISORDER; OVARY DISEASE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TUMOR VOLUME; UTERUS BLEEDING; UTERUS MYOMA; WEIGHT GAIN;

EID: 0347986535     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2003.06.009     Document Type: Article

References (27)

1. Ligon A.H., Morton C. Leiomyomata heritability and cytogenetic studies . Hum Reprod Update. 7:2001;8-14.
2. Townsend D., Sparkes R., Baluda M., McCleelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol. 107:1970;1168-1173.
3. Buttram V., Reiter R. Uterine leiomyomata etiology, symptomatology and management . Fertil Steril. 36:1981;433-445.
4. Ichimura T., Kawamura N., Ito F., Shibata S., Minakuchi K., Tsujimura A., et al. Sex steroid receptors in human myometrium and fibroids changes during the menstrual cycle and gonadotropin-releasing hormone treatment . J Clin Endocrinol Metab. 83:1998;4092-4096.
5. Jirecek S., Wieser F., Kurz C., Albrecht A., Nagele F., Wenzl R. Technik und Resultate der laparoskopisch konservativen, organerhaltenden Myomenukleation. Wien Klin Wochenschr. 112:2000;276-280.
6. Nisolle M., Gillerot S., Casanas-Roux F., Squifflet J., Berliere M., Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod. 14:1999;2844-2850.
7. Scialli A.R., Levi A.J. Intermittent leuprolide acetate for the nonsurgical management of women with leiomyomata uteri. Fertil Steril. 74:2000;540-546.
8. Dawood M., Lewis V., Ramos J. Cortical and trabecular bone mineral content in women with endometriosis effect of gonadotropin-releasing hormone agonist and danazol . Fertil Steril. 52:1989;21-26.
9. Grese T.A., Sluka J.P., Bryant H.U., Cullinan G.J., Glasebrook A.L., Jones C.D., et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A. 94:1997;14105-14110.
10. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators . JAMA. 282:1999;637-645.
11. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation . JAMA. 281:1999;2189-2197.
12. Barrett-Connor E., Grady D., Sashegyi A., Anderson P.W., Cox D.A., Hoszowski K., et al. The MORE Investigators (Multiple Outcomes of Raloxifene Evaluation) Raloxifene and cardiovascular events in osteoporotic postmenopausal women four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial . JAMA. 287:2002;847-857.
13. Goldstein S.R., Scheele W.H., Rajagopalan S.K., Wilkie J.L., Walsh B.W., Parsons A.K. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol. 95:2000;95-103.
14. Cohen F.J., Watts S., Shah A., Akers R., Plouffe L. Jr. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol. 95:2000;104-110.
15. Baker V., Draper M., Paul S., Allerheiligen S., Glant M., Shifren J., et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metabol. 83:1998;6-13.
16. Fuchs-Young R., Howe S., Hale L., Miles R., Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana. Mol Carcinog. 17:1996;151-159.
17. Porter K.B., Tsibris J.C., Porter G.W., Fuchs-Young R., Nicosia S.V., O'Brien W.F., et al. Effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol. 179:1998;1283-1287.
18. Palomba S., Sammartino A., Di Carlo C., Affinito P., Zullo F., Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril. 76:2001;38-43.
19. Palomba S., Orio F. Jr, Morelli M., Russo T., Pellicano M., Zupi E., et al. Raloxifene administration in premenopausal women with uterine leiomyomas a pilot study . J Clin Endocrinol Metab. 87:2002;3603-3608.
20. Lee A., Sator M., Kratochwil A., Deutinger J., Vytiska-Binsdorfer E., Bernaschek G. Endometrial volume change during spontaneous menstrual cycles volumetry by transvaginal three-dimensional ultrasound . Fertil Steril. 68:1997;831-836.
21. Deligdisch L., Hirschmann S., Altchek A. Pathologic changes in gonadotropin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril. 67:1997;837-841.
22. Sadan O., Ginath S., Sofer D., Rotmensch S., Debby A., Glezerman M., et al. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata - a pilot study. Eur J Obstet Gynecol Reprod Biol. 96:2001;183-186.
23. Walker C.L., Burroughs K.D., Davis B., Sowell K., Everitt J.I., Fuchs-Young R. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig. 7:2000;249-256.
24. Rannevik G., Jeppsson S., Johnell O., Bjerre B., Laurell-Borulf Y., Svanberg L. A longitudinal study of the perimenopause transition altered profiles of steroid and pituitary hormones, SHGB and bone mineral density . Maturitas. 21:1995;103-113.
25. Palomba S., Russo T., Orio F. Jr, Tauchmanova L., Zupi E., Panici P.L., et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas a prospective, randomized, single-blind, placebo-controlled clinical trial . Hum Reprod. 17:2002;321-329.
26. Snyder K.R., Sparano N., Malinowski J.M. Raloxifene hydrochloride. Am J Health Syst Pharm. 57:2000;1669-1675.
27. Nuttall M.E., Bradbeer J.N., Stroup G.B., Nadeau D.P., Hoffman J., Zhao H., et al. Idoxifene a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats . Endocrinology. 139:1998;5224-5234.